Rapid Diagnosis Offered by Molecular Diagnostics Methods for Range of Infectious Diseases to Bolster Uptake

The growing demand for diagnostic platform for the reliable and rapid diagnosis of a broad range of infectious diseases has led to substantial advances in molecular diagnostics. The advent of a variety of reliable diagnostic tests to diagnose sexually-transmitted infections, such as those caused by Neisseria gonorrhea and Chlamydia trachomatis, has opened up lucrative growth avenues over the past two decades. Constant advancements are being made in the market to reduce the computation time of multiplexed platforms and offer easy mode of operations. Recent technologies also tend to improve the accuracy of results and facilitate their adoption in point-of-care settings. These developments are further anticipated to play a crucial role in achieving the goal of personalized healthcare. 

Various molecular diagnostics are widely employed by clinicians in diagnosing or predicting genetic diseases, various cancer types, hospital-acquired infections, and hepatitis. Catalyzed by the rising geriatric population and fueled by recent advances made in molecular biology in various regions, the molecular diagnostics market is expected to witness exciting times ahead. According to Transparency Market Research (TMR), the market is projected to rise at a CAGR of 11.6% from 2016 and 2025. Growing at this rate, the market is predicted to reach US$18.9 bn by the end of the forecast period. 

Which molecular diagnostic technologies are expected to witness widespread adoption along the forecast period?

The major technology types used in molecular diagnostics are polymerase chain reaction (PCR) and real-time PCR, microarray, hybridization, transcription-mediated amplification, and next-generation sequencing. Among these, polymerase chain reaction and real-time PCR was the dominant segment. In 2016, the PCR and real-time PCR segment held the leading share of 39.1% of the worldwide market. The growth of the segment is attributable to the cost-effectiveness in amplifying of small fragments of DNA or RNA, since the method can produce a large number of copies of the target template sequence. 

Meanwhile, the next-generation sequencing segment is predicted to grow at a rapid pace. The impressive growth is attributed to advanced throughput, rapid generation of test results, and better flexibility. These features help in delivering hundreds of gigabases (Gb) of data in a single sequencing run. 

The rise in grants and funding from leading national organizations has helped players in expanding their product portfolio. Atlas Genetics Limited, a U.K.-based developer of diagnostic platform, announced on August 15, 2017 that it received a two-year phase II contract from Innovate UK, to expand molecular diagnostic methods under its io rapid diagnostic platform for diagnosing sexually transmitted infections. The grant is valued at US$2.6 million (£2 million) and will prove helpful to the company in evaluating the scope of the platform in multiple UK sexual health clinics. In addition, Atlas Genetics also intends to partner with Aquarius Population Health London to assess the benefits of point-of-care testing for sexual infections. The grant will also be used for developing its Multi-STI diagnostic platform, which offers multi-pathogen test for Neisseria gonorrhoea, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis. Such developments expand the armamentarium of methods currently available with clinicians in infectious disease diagnosis. 

Which regions are predicted to offer lucrative avenues in the coming years? 

Geographically, North America accounted for the major share in 2016 and the regional market is predicted to thrive throughout the forecast period. The dominance of the regional market is fueled by a well-structured healthcare infrastructure.  The growth of the market is fueled by the increasing prevalence of a number of infectious diseases and various cancer types. In addition, the growing demand for affordable and reliable molecular diagnostic tests among patients is a key factor expected to boost the market. 

Meanwhile, the Asia Pacific market for molecular diagnostics is predicted to offer lucrative growth avenues. The demand for molecular diagnostic methods in several developed and developing countries of the region is propelled by substantial improvements of healthcare services and the rising awareness of molecular diagnostic tools. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports